TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06561152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp
Description: Tagraxofusp is administered by intravenous infusion (IV) over 15 minutes for 3 consecutive days of a 28-day cycle. (days 4-6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp
Description: Tagraxofusp is administered by intravenous infusion (IV) over 15 minutes for 3 consecutive days of a 28-day cycle. (days 4-6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp
Description: Tagraxofusp is administered by intravenous infusion (IV) over 15 minutes for 3 consecutive days of a 28-day cycle. (days 4-6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp
Description: Tagraxofusp is administered by intravenous infusion (IV) over 15 minutes for 3 consecutive days of a 28-day cycle. (days 4-6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine (CLAD)
Description: Cladribine 5mg/m2 IV once daily on days 1-3 (DL1) Cladribine 5mg/m2 IV once daily on days 1-4 (DL2) Cladribine 5mg/m2 IV once daily on days 1-5 (DL3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine (CLAD)
Description: Cladribine 5mg/m2 IV once daily on days 1-3 (DL1) Cladribine 5mg/m2 IV once daily on days 1-4 (DL2) Cladribine 5mg/m2 IV once daily on days 1-5 (DL3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine (CLAD)
Description: Cladribine 5mg/m2 IV once daily on days 1-3 (DL1) Cladribine 5mg/m2 IV once daily on days 1-4 (DL2) Cladribine 5mg/m2 IV once daily on days 1-5 (DL3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine (CLAD)
Description: Cladribine 5mg/m2 IV once daily on days 1-3 (DL1) Cladribine 5mg/m2 IV once daily on days 1-4 (DL2) Cladribine 5mg/m2 IV once daily on days 1-5 (DL3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 20mg/m2 IV daily days 1-5 (DL1) Cytarabine 20mg/m2 IV daily days 1-7(DL2) cytarabine 20mg/m2 IV daily days 1-10 (DL3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 20mg/m2 IV daily days 1-5 (DL1) Cytarabine 20mg/m2 IV daily days 1-7(DL2) cytarabine 20mg/m2 IV daily days 1-10 (DL3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 20mg/m2 IV daily days 1-5 (DL1) Cytarabine 20mg/m2 IV daily days 1-7(DL2) cytarabine 20mg/m2 IV daily days 1-10 (DL3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 20mg/m2 IV daily days 1-5 (DL1) Cytarabine 20mg/m2 IV daily days 1-7(DL2) cytarabine 20mg/m2 IV daily days 1-10 (DL3)
Study: NCT06453031

Intervention type: PROCEDURE
Intervention: Gastric Ischemic Preconditioning Before Esophagectomy
Description: Does embolization of the left gastric artery prior oesophagectomy reduce postoperative complications, particularly anastomotic leaks and ischemia of the gastric conduit?
Study: NCT06348095

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The experimental phase of this study had last 14 days, and each patient will make 4 visits (d0, d3, d7, d14).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The experimental phase of this study had last 14 days, and each patient will make 4 visits (d0, d3, d7, d14).
Study: NCT05173090

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaïne 0,5% for appendectomy or cholecystectomy surgery
Description: Visual analog scale 15 min after arrival in the recovery room, then H+4, H+6, H+12, H+24 and one week after the operation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaïne 0,5% for appendectomy or cholecystectomy surgery
Description: Visual analog scale 15 min after arrival in the recovery room, then H+4, H+6, H+12, H+24 and one week after the operation
Study: NCT05469919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Ceralasertib taken orally
Study: NCT05062356

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Bupivacaine Hydrochloride 0.25% Injection Solution_#2
Description: 40cc
Study: NCT05790694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM9378 (SKB378) Injection
Description: Strength: 225 mg (1.5 mL)/vial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Strength: 225 mg (1.5 mL)/vial
Study: NCT05940350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation Stroke Coaching of Program (TeleSCoP) group
Description: The sampling criteria will be assigned to the intervention (TeleSCoP) and control groups by stratified randomization (1:1) in patients with acute ischemic stroke. A three-month telerehabilitation-based coaching intervention will be applied to stroke patients in the intervention group. Within the scope of telerehabilitation-based coaching initiative, coaching initiatives will be planned for the management of symptoms and complications for modifiable risk factors. Patients in the intervention group will receive discharge education with the education booklet prepared on the 4th or 5th day in the hospital, and informative videos prepared in cooperation with the multidisciplinary team will be shared with the patients. Patients will be called by phone at weeks 1, 2, 3, 4, 6, 8, and 10. The patients in the control group will be given the Stroke Education Brochure of the Ministry of Health and they will benefit from routine hospital services for three months.
Study: NCT06488664

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GNR-068
Description: GNR-068 was administered subcutaneously at weeks 0 and 4 weeks then every 12 weeks thereafter until week 52.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stelara®
Description: Stelara® was administered subcutaneously at weeks 0 and 4 weeks then every 12 weeks thereafter until week 28 and then all patients receive GNR-068 45 mg until week 52.
Study: NCT05589987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: power mobility
Description: Sessions of adjustment, adaptation and choice of the device for training will be carried out. Once the cars are fully adapted and conditioned to the environment and needs of the family and the child, the intervention will begin.~The study will take place in the child's natural environment for 12 weeks. Three 40-minute sessions per week will be held, each session includes: 1) configuration of the environment (families will be instructed by the therapists to adapt the environment to the child's situation and their conditions for driving the car): 5 min ; 2) natural play as a warm-up activity: 5 min; and 3) mobility and social training with cars: 30 min. The 30-minute driving session will involve participants learning cause and effect concepts by driving the toy car (press the button to move and release to stop). The therapist and caregivers will use verbal cues to encourage children to drive and explore the environment. All sessions will be video and audio recorded.
Study: NCT05641935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur Hexafluoride Lipid Microspheres
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Ultrasound
Description: Undergo CEUS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Review electronic medical record
Study: NCT05062356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride 0.25% Injection Solution_#2
Description: 40cc

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: EPINEPHrine 1:200,000 / Prilocaine HCl 4 % 1.8 ML Cartridge
Description: 10cc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPINEPHrine 1:200,000 / Prilocaine HCl 4 % 1.8 ML Cartridge
Description: 10cc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPINEPHrine 1:200,000 / Prilocaine HCl 4 % 1.8 ML Cartridge
Description: 10cc

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Bupivacaine Hydrochloride 0.5% Injection Solution_#2
Description: 20cc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride 0.5% Injection Solution_#2
Description: 20cc

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ketorolac
Description: 15mg

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ketorolac
Description: 15mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: 15mg
Study: NCT05194150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-diffractive monofocal IOL
Description: Rayone EMV
Study: NCT04825028

Intervention type: DEVICE
Intervention: Angiography-drived Index of Microcirculatory Resistance
Description: From coronary angiographic images, angiography-derived IMR will be calculated based on mathematical calculation.~Angiography-derived IMR = (hyperemic Pa x angiography-derived FFR) x (vessel length / {K x V diastole}).~Hyperemic Pa will be estimated from resting Pa according to prespecified equation.

Intervention type: DEVICE
Intervention: Angiography-drived Index of Microcirculatory Resistance
Description: From coronary angiographic images, angiography-derived IMR will be calculated based on mathematical calculation.~Angiography-derived IMR = (hyperemic Pa x angiography-derived FFR) x (vessel length / {K x V diastole}).~Hyperemic Pa will be estimated from resting Pa according to prespecified equation.

Intervention type: DEVICE
Intervention: Angiography-drived Index of Microcirculatory Resistance
Description: From coronary angiographic images, angiography-derived IMR will be calculated based on mathematical calculation.~Angiography-derived IMR = (hyperemic Pa x angiography-derived FFR) x (vessel length / {K x V diastole}).~Hyperemic Pa will be estimated from resting Pa according to prespecified equation.
Study: NCT05194150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard EDOF IOL
Description: Acrysof IQ Vivity
Study: NCT05129956

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Covidien Emprint Ablation System with Thermosphere Technology
Description: The ablation time and wattage are determined according to the size of the tumor. The wattages are respectively 45W, 75W, and 100W, and the maximum time is 10 minutes
Study: NCT06172413

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation (tACS)
Description: Three conductive electrodes will be applied to the scalp: one 4.45 × 9.53 cm electrode placed over the forehead (Fpz, Fp1, and Fp2 in the 10/20 international placement system) and two 3.18 × 3.81 cm electrodes over the mastoid areas.~The tACS stimulation waveform includes ramp-up and ramp-down periods of 180 and 12 s, respectively. It is a square-wave with an average amplitude of 15 mA and is equally distributed from the frontal region to the mastoid areas (amplitudes are reported as zero-to-peak).~Each subject will receive 40 sessions of tACS intervention during 4 consecutive weeks at a fixed day time twice per day (once in morning and afternoon, respectively) from Monday through Friday. Each session lasts 40 min.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tACS
Description: Sham tACS
Study: NCT06467123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue Intervention
Description: Participants will attend eight sessions. During each session, participants will receive education on pain neuroscience education, stress management, and maintaining physical activity. Participants will complete shoulder stretching and strengthening exercises according to a graded exercise protocol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biopsychosocial Intervention
Description: Participants will attend eight sessions. During each session, participants will receive education on pain neuroscience education, stress management, and maintaining physical activity. Participants will complete shoulder stretching and strengthening exercises according to a graded exercise protocol.
Study: NCT05822310

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency thermocoagulation to the articular branches of the femoral and obturatory nerves
Description: Patients are operated under sedation in the operating room. C-arm fluoroscopy device is used for imaging purposes for radiofrequency thermocoagulation process. In order to prevent vascular injury, the needle is advanced under the guidance of ultrasonography. There are target points determined in fluoroscopy for the femoral nerve and the obturatory nerve. Before the thermocoagulation procedure, local anesthetic and steroid are injected into each of the target points.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intraairticular steroid injection
Description: The patients were placed in the supine position in the operating room. The patient was stained sterile with povidone iodide. The femoral neck was detected under ultrasonography and the joint capsule was entered with a 22G 9 cm spinal needle. Then, 5 cc bupivacaine and 5 mg betamethasone were given and the procedure was terminated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pericapsular nerve group (PENG) block
Description: The patients were placed in the supine position in the operating room. The patient was stained sterile with povidone iodide. The high-frequency linear ultrasonography probe was placed on the anterior superior iliacspina (ASIS). Later, the anterior inferior iliac spine (AIIS) was detected by descending caudally. Afterwards, the probe was brought to the oblique position and AIIS, iliopubikeminence, psoas muscle and tendon were seen. Using a 22G 90-mm Quinckespinal needle, the tendon of the iliopsoas muscle was entered in the lateral-medial direction in the in-plane plane and bone contact was achieved. After negative aspiration, 15 ml of 0.5% bupivacaine were administered by seeing the appropriate drug distribution.
Study: NCT05669222

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FAST Technique
Description: The next-generation QFR (μQFR) introduces a more intelligent algorithm and supports single-projection rapid calculation with a diagnostic accuracy of 93.0% compared with FFR; Computational RWS technique facilitates the assessment of lesion vulnerability.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Angiography
Description: Coronary angiography is a procedure that uses contrast under x-ray pictures to detect stenosis in the coronary arteries.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Angiography
Description: Coronary angiography is a procedure that uses contrast under x-ray pictures to detect stenosis in the coronary arteries.
Study: NCT05859113

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ziacom Galaxy dental implant with internal connical prosthetic connection
Description: Placement and restoration of a single Ziacom Galaxy dental implant with internal connical prosthetic connection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ziacom Zinic dental implant with internal hexagonal prosthetic connection
Description: Placement and restoration of a single Ziacom Zinic dental implant with internal hexagonal prosthetic connection
Study: NCT06145919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking (EFT)
Description: The adapted episodic future thinking (EFT) intervention will focus on generation of vivid, substance-free, rewarding events that could happen in the future with their children.
Study: NCT04859335

Intervention type: RADIATION
Group type: OTHER
Intervention: gammaknife radiosurgery
Description: Patients will undergo questionnaires before the gammaknife radiosurgery, then one year and three years after the intervention.
Study: NCT06145919

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Episodic Recent Thinking (ERT)
Description: In the episodic recent thinking (ERT) condition, the participant will instead describe in vivid details events that have occurred in the recent past.
Study: NCT05880147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Consent App
Description: Family will receive their study information and consent form in an app on a tablet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional paper-based consent
Description: Patient/family will receive their study information and consent on a traditional paper form
Study: NCT04815551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-380
Description: AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-380
Description: AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-380
Description: AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-380
Description: AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-380
Description: AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-380
Description: AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-380
Description: AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is sterile liquid for IV infusion.
Study: NCT05766228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-Based Intercultural Midwifery Training
Description: The training program is a program where students can log in via the internet using the password given to them by a smartphone or computer. The web base is compatible with mobile phones and is suitable for use at any time of the day. The trainings were prepared and explained by the researchers on the web page in the form of a video presentation with the theory-based didactic classroom technique using a Power Point presentation. The training program covered six weeks and consisted of two sessions of 30 minutes each week. In the first five weeks, general information on the development of intercultural midwifery and the main components of cultural competence models are explained. In the last week, training was completed with case presentations in the form of two sessions.
Study: NCT04093817

Intervention type: DEVICE
Intervention: cardio pulmonary bypass machine
Description: cardio pulmonary bypass machine is a machine that work to compensate for the function of the heart and the lungs in the operation
Study: NCT05394740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: 90 mg administered orally, once daily for 21 consecutive days followed by 7 days off~\*Repeat every 4 weeks as Regorafenib therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: CohotA:360 mg administered intravenously, every 3 weeks \*Administered on the same day as CapeOX therapy Cohort B: 240 mg administered intravenously, every 2 weeks \*Administered on the same day as FOLFOX therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CapeOX
Description: For Cohort A only~* Capecitabine 1,000 mg/m\^2 administered orally, twice daily (Days 1 to 14 continuous dosing of CapeOX therapy)~* Oxaliplatin 130 mg/m\^2 administered intravenously (Day 1 of CapeOX therapy) \*Repeat every 3 weeks as CapeOX therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: For Cohort B only~* Leucovorin 400 mg/m\^2 administered intravenously (Day 1 of FOLFOX therapy)~* Fluorouracil 400 mg/m\^2 administered intravenously (Day 1 of FOLFOX therapy) and 1,200 mg/m2 administered intravenously (Days 1 to 2 of FOLFOX therapy)~* Oxaliplatin 85 mg/m\^2 administered intravenously (Day 1 of FOLFOX therapy) \*Repeat every 2 weeks as FOLFOX therapy
Study: NCT06166914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraoperative infusion of 5-FU (200 µg/ml) and LMWH (5 IU/ml)
Description: After informed consent, children under 14 years of age with high-risk PRRD underwent pars plana vitrectomy and silicone oil injection with scleral buckle divided into 2 groups in prospective randomized trial. Group A received intraoperative infusion of 5-FU (200 µg/ml) and LMWH (5 IU/ml).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After informed consent, children under 14 years of age with high-risk PRRD underwent pars plana vitrectomy and silicone oil injection with scleral buckle divided into 2 groups in prospective randomized trial. Group B received infusion of normal saline.
Study: NCT05929924

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Extra virgin olive oil
Description: EVOO will be included in the participant's daily diet for 6 months
Study: NCT04859478

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Dual energy / spectral portal venous chest computed tomography
Description: Each patient undergoes an additional dual energy / spectral chest CT in addition to standard care CTPA. The intervention is performed immediately after standard care CTPA.
Study: NCT04903184

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RUTI® vaccine
Description: Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli in a total volum of 0,3mL.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiological serum, 0.9% NaCl, will be used as a placebo.
Study: NCT06222918

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Margin Elevation (G-ænial Universal Injectable)
Description: Deep margin elevation (DME), or coronal margin relocation (CMR), is a procedure used to raise or reposition sub-gingival margins into supra-gingival margins using several materials to increase marginal integrity and bonding strength